NCT03583307 is a NA clinical trial of Sirolimus in Vascular Anomaly, sponsored by West China Hospital.

Who is sponsoring NCT03583307?

NCT03583307 is sponsored by West China Hospital.

What drugs are being tested in NCT03583307?

Interventions in NCT03583307: Sirolimus.

What condition does NCT03583307 study?

NCT03583307 studies Vascular Anomaly.

Is NCT03583307 still recruiting?

NCT03583307 is currently completed. Last updated 15 March 2022.

Last reviewed 2022-03-15 · How we verify

NCT03583307

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Efficacy and Safety of Sirolimus to Vascular Anomalies

Completed NA Last updated 15 March 2022

What this trial tests

NA trial testing Sirolimus in Vascular Anomaly in 126 participants. Completed in 19 February 2021.

Timeline

1 June 2018

Primary endpoint
19 February 2021

19 February 2021

Quick facts

Lead sponsor	West China Hospital
Phase	NA
Status	Completed
Study type	INTERVENTIONAL
Allocation	na
Design	single group
Masking	none
Primary purpose	treatment
Enrollment	126
Start date	1 June 2018
Primary completion	19 February 2021
Estimated completion	19 February 2021
Sites	1 location across China

Drugs / interventions tested

Sirolimus (sirolimus) — full drug profile →

Conditions studied

Vascular Anomaly — all drugs for Vascular Anomaly →

Sponsor

West China Hospital

Who can join

Adults 0 to 18, any sex, with Vascular Anomaly. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

To evaluate the safety and efficacy of Sirolimus in complicated vascular anomalies in Chinese children

Publications & conference data

2 peer-reviewed publications reference this trial (live from Europe PMC):

Congenital Vascular and Lymphatic Diseases.
Jung R, Trivedi CM. · · 2024 · cited 6× · PMID 38900856 · DOI 10.1161/circresaha.124.323181
PI3K/AKT/mTOR axis in vascular malformations: from molecular insights to targeted clinical trials.
Zheng YY, Hua C, Lin XX. · · 2025 · cited 1× · PMID 41430313 · DOI 10.1186/s13023-025-04115-2

Verify or expand the search:

Other trials of Sirolimus

Trials testing the same drug.

NCT07542314 — Study to Evaluate the Safety and Effectiveness of ELEVIDYS in Participants With Duchenne Muscular Dystrophy Treated in a · Phase 4 · not yet recruiting
NCT06876142 — Combination Therapy (Mirdametinib and Sirolimus) for RAS Mutated Relapsed Refractory Multiple Myeloma · Phase 1, PHASE2 · suspended
NCT07052929 — Study of ASP2957 in Male Participants With X-linked Myotubular Myopathy Who Need Ventilators · Phase 1, PHASE2 · recruiting
NCT04370795 — Matched Related and Unrelated Donor Stem Cell Transplantation for Severe Combined Immune Deficiency (SCID): Busulfan-bas · Phase 1, PHASE2 · withdrawn
NCT07162038 — Phase I Trial Integrating HLA-Haploidentical Anti-CD19 CAR-T Cells With Post-Transplantation Cyclophosphamide-Based HLA- · Phase 1 · recruiting

Other recruiting trials for Vascular Anomaly

Currently open trials in the same condition.

NCT04464655 — A 10-Minute Cardiovascular Magnetic Resonance Protocol for Cardiac Disease · recruiting

Other West China Hospital trials

Trials by the same sponsor.

NCT07583654 — Safety, Tolerability, and Preliminary Antitumor Activity of Cationic Peptide-IL22BP mRNA in Advanced Solid Tumors · Phase 1 · not yet recruiting
NCT07583914 — Safety, Tolerability, and Preliminary Antitumor Activity of Non-Cationic Peptide-CD47 siRNA in Advanced Solid Tumors · Phase 1 · not yet recruiting
NCT07492914 — Neoadjuvant Sacituzumab Govitecan Plus Tagitanlimab for Resectable Head and Neck Squamous Cell Carcinoma · Phase 2 · recruiting
NCT07507097 — Study on the Optimal Head Position for Patients With Severe Acute Ischemic Stroke · NA · not yet recruiting
NCT07472933 — Vebotolimab Combined With Ptorlimab for EGFR-positive Refractory Advanced Biliary Tract Malignancies · Phase 2 · not yet recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT03583307 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by West China Hospital
Last refreshed: 15 March 2022

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03583307.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing